{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:33:16Z","timestamp":1767648796313,"version":"build-2065373602"},"reference-count":66,"publisher":"Elsevier BV","issue":"31","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016156","name":"US Army Medical Research and Development Command","doi-asserted-by":"publisher","award":["W81XWH-10-C-0005"],"award-info":[{"award-number":["W81XWH-10-C-0005"]}],"id":[{"id":"10.13039\/100016156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.vaccine.2022.05.076","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T15:06:38Z","timestamp":1654873598000},"page":"4270-4280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Norovirus-VLPs expressing pre-erythrocytic malaria antigens induce functional immunity against sporozoite infection"],"prefix":"10.1016","volume":"40","author":[{"given":"Cosette G.","family":"Schneider","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Fey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vince","family":"Gerbasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana","family":"Savransky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Batt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Bergmann-Leitner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelina","family":"Angov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.05.076_b0005","unstructured":"WHO World Malaria Report; 2021."},{"key":"10.1016\/j.vaccine.2022.05.076_b0010","doi-asserted-by":"crossref","unstructured":"Penny MA, Maire N, Studer A, Schapira A, Smith TA. What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines. PLoS One 2008;3:e3193.","DOI":"10.1371\/journal.pone.0003193"},{"issue":"7","key":"10.1016\/j.vaccine.2022.05.076_b0015","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1365-3156.2009.02287.x","article-title":"From malaria control to eradication: the WHO perspective","volume":"14","author":"Mendis","year":"2009","journal-title":"Trop Med Int Health"},{"issue":"3","key":"10.1016\/j.vaccine.2022.05.076_b0020","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1086\/600120","article-title":"Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S\/AS01B and RTS, S\/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection","volume":"200","author":"Kester","year":"2009","journal-title":"J Infect Dis"},{"issue":"52","key":"10.1016\/j.vaccine.2022.05.076_b0025","doi-asserted-by":"crossref","first-page":"7452","DOI":"10.1016\/j.vaccine.2015.09.096","article-title":"Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines","volume":"33","author":"Richie","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.05.076_b0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS, S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"Rts","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.05.076_b0035","article-title":"Efficacy and safety of the RTS, S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites","volume":"11","author":"Rts","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2022.05.076_b0040","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/s12936-016-1435-y","article-title":"Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity","volume":"15","author":"Hickey","year":"2016","journal-title":"Malar J"},{"issue":"7642","key":"10.1016\/j.vaccine.2022.05.076_b0045","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature21060","article-title":"Sterile protection against human malaria by chemoattenuated PfSPZ vaccine","volume":"542","author":"Mordm\u00fcller","year":"2017","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.vaccine.2022.05.076_b0050","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1073\/pnas.1615324114","article-title":"Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection","volume":"114","author":"Lyke","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.vaccine.2022.05.076_b0055","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","article-title":"Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial","volume":"17","author":"Sissoko","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.05.076_b0060","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89154","article-title":"Protection against Plasmodium falciparum malaria by PfSPZ Vaccine","volume":"2","author":"Epstein","year":"2017","journal-title":"JCI Insight"},{"issue":"9","key":"10.1016\/j.vaccine.2022.05.076_b0065","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0966-842X(03)00208-7","article-title":"Virus-like particles as immunogens","volume":"11","author":"Noad","year":"2003","journal-title":"Trends Microbiol"},{"issue":"12","key":"10.1016\/j.vaccine.2022.05.076_b0070","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1586\/14760584.2015.1096781","article-title":"Malaria vaccine based on self-assembling protein nanoparticles","volume":"14","author":"Burkhard","year":"2015","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2022.05.076_b0075","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s12250-016-3756-y","article-title":"Virus like particle-based vaccines against emerging infectious disease viruses","volume":"31","author":"Liu","year":"2016","journal-title":"Virol Sin"},{"issue":"11","key":"10.1016\/j.vaccine.2022.05.076_b0080","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.tibtech.2013.09.002","article-title":"Virus-like particle-based human vaccines: quality assessment based on structural and functional properties","volume":"31","author":"Zhao","year":"2013","journal-title":"Trends Biotechnol"},{"issue":"11","key":"10.1016\/j.vaccine.2022.05.076_b0085","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1128\/JVI.00219-07","article-title":"Structural basis for the recognition of blood group trisaccharides by norovirus","volume":"81","author":"Cao","year":"2007","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.05.076_b0090","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.copbio.2013.02.008","article-title":"Virus-like particles: the future of microbial factories and cell-free systems as platforms for vaccine development","volume":"24","author":"Rodr\u00edguez-Limas","year":"2013","journal-title":"Curr Opin Biotechnol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.076_b0095","first-page":"222","article-title":"Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates","volume":"19","author":"Pillet","year":"2022","journal-title":"CellMol Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.05.076_b0100","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41591-021-01370-1","article-title":"Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19","volume":"27","author":"Ward","year":"2021","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.vaccine.2022.05.076_b0105","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Rold\u00e3o","year":"2010","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.076_b0110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev.immunol.15.1.235","article-title":"Neutralizing antiviral B cell responses","volume":"15","author":"Bachmann","year":"1997","journal-title":"Annu Rev Immunol"},{"issue":"16","key":"10.1016\/j.vaccine.2022.05.076_b0115","doi-asserted-by":"crossref","first-page":"9477","DOI":"10.1073\/pnas.95.16.9477","article-title":"T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles","volume":"95","author":"Fehr","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.vaccine.2022.05.076_b0120","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1586\/14760584.6.3.381","article-title":"Virus-like particles: flexible platforms for vaccine development","volume":"6","author":"Chackerian","year":"2007","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2022.05.076_b0125","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.copbio.2007.10.013","article-title":"Virus-like particles-universal molecular toolboxes","volume":"18","author":"Ludwig","year":"2007","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.vaccine.2022.05.076_b0130","first-page":"315","article-title":"Enhanced proliferative cellular responses to HIV-1 V3 peptide and gp120 following immunization with V3: Ty virus-like particles","volume":"77","author":"Harris","year":"1992","journal-title":"Immunology"},{"issue":"5","key":"10.1016\/j.vaccine.2022.05.076_b0135","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.0818-9641.2004.01271.x","article-title":"Vaccines that facilitate antigen entry into dendritic cells","volume":"82","author":"Gamvrellis","year":"2004","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.076_b0140","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/viro.1994.1175","article-title":"Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles","volume":"200","author":"Wagner","year":"1994","journal-title":"Virology"},{"issue":"11","key":"10.1016\/j.vaccine.2022.05.076_b0145","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.4049\/jimmunol.169.11.6120","article-title":"Determinants of autoantibody induction by conjugated papillomavirus virus-like particles","volume":"169","author":"Chackerian","year":"2002","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2022.05.076_b0150","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1128\/JVI.00332-14","article-title":"Human metapneumovirus virus-like particles induce protective B and T cell responses in a mouse model","volume":"88","author":"Cox","year":"2014","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2022.05.076_b0155","doi-asserted-by":"crossref","first-page":"8056","DOI":"10.1128\/jvi.68.12.8056-8063.1994","article-title":"CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection","volume":"68","author":"Matloubian","year":"1994","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2022.05.076_b0160","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1586\/erv.11.57","article-title":"The RTS, S vaccine candidate for malaria","volume":"10","author":"Regules","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.076_b0165","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1084\/jem.20101488","article-title":"The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host","volume":"208","author":"Coppi","year":"2011","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.vaccine.2022.05.076_b0170","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","article-title":"RTS, S\/AS01 vaccine (Mosquirix): an overview","volume":"16","author":"Laurens","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2022.05.076_b0175","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/1475-2875-8-312","article-title":"Immunological mechanisms underlying protection mediated by RTS, S: a review of the available data","volume":"8","author":"Moorthy","year":"2009","journal-title":"Malar J"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.076_b0180","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-10-224","article-title":"Design of a phase III multicenter trial to evaluate the efficacy of the RTS, S\/AS01 malaria vaccine in children across diverse transmission settings in Africa","volume":"10","author":"Leach","year":"2011","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2022.05.076_b0185","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","article-title":"A phase 3 trial of RTS, S\/AS01 malaria vaccine in African infants","volume":"367","author":"Rts","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.076_b0190","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJM199701093360202","article-title":"A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS, S Malaria Vaccine Evaluation Group","volume":"336","author":"Stoute","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.05.076_b0195","unstructured":"WHO recommends groundbreaking malaria vaccine for children at risk. Geneva: World Health Organization; 2021."},{"key":"10.1016\/j.vaccine.2022.05.076_b0200","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1365-2958.2005.05024.x","article-title":"CelTOS, a novel malarial protein that mediates transmission to mosquito and vertebrate hosts","volume":"59","author":"Kariu","year":"2006","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.vaccine.2022.05.076_b0205","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.20621","article-title":"Malaria parasite CelTOS targets the inner leaflet of cell membranes for pore-dependent disruption","volume":"5","author":"Jimah","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.vaccine.2022.05.076_b0210","doi-asserted-by":"crossref","unstructured":"Bergmann-Leitner ES, et al. Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei. PLoS One 2010;5:e12294.","DOI":"10.1371\/journal.pone.0012294"},{"issue":"35","key":"10.1016\/j.vaccine.2022.05.076_b0215","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1016\/j.vaccine.2011.06.053","article-title":"Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS","volume":"29","author":"Bergmann-Leitner","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.05.076_b0220","doi-asserted-by":"crossref","unstructured":"Bergmann-Leitner ES, et al. Computational and experimental validation of B and T-cell epitopes of the in vivo immune response to a novel malarial antigen. PLoS One 2013;8:e71610.","DOI":"10.1371\/journal.pone.0071610"},{"issue":"6","key":"10.1016\/j.vaccine.2022.05.076_b0225","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/infdis\/171.6.1576","article-title":"Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine","volume":"171","author":"Gordon","year":"1995","journal-title":"J Infect Dis"},{"issue":"17-18","key":"10.1016\/j.vaccine.2022.05.076_b0230","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.vaccine.2005.01.142","article-title":"Towards an RTS, S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research","volume":"23","author":"Heppnerjr","year":"2005","journal-title":"Vaccine"},{"issue":"35","key":"10.1016\/j.vaccine.2022.05.076_b0235","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.1016\/j.vaccine.2011.03.041","article-title":"Four year immunogenicity of the RTS, S\/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial","volume":"29","author":"Aide","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.076_b0240","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1128\/JVI.01835-10","article-title":"Norovirus P particle, a novel platform for vaccine development and antibody production","volume":"85","author":"Tan","year":"2011","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.05.076_b0245","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2217\/nnm.12.62","article-title":"Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus","volume":"7","author":"Tan","year":"2012","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.vaccine.2022.05.076_b0250","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.provac.2011.07.004","article-title":"Norovirus P particle as a platform for antigen presentation","volume":"4","author":"Tan","year":"2011","journal-title":"Procedia Vaccinol"},{"key":"10.1016\/j.vaccine.2022.05.076_b0255","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11090472","article-title":"Norovirus capsid protein-derived nanoparticles and polymers as versatile platforms for antigen presentation and vaccine development","volume":"11","author":"Tan","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.vaccine.2022.05.076_b0260","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12934-014-0134-z","article-title":"Secreted production of assembled Norovirus virus-like particles from Pichia pastoris","volume":"13","author":"Tome-Amat","year":"2014","journal-title":"Microb Cell Fact"},{"issue":"44","key":"10.1016\/j.vaccine.2022.05.076_b0265","doi-asserted-by":"crossref","first-page":"7670","DOI":"10.1016\/j.vaccine.2011.07.139","article-title":"A candidate dual vaccine against influenza and noroviruses","volume":"29","author":"Xia","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.05.076_b0270","doi-asserted-by":"crossref","unstructured":"Gong X, et al. Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B. Emerg Microbes Infect 2016;5:e51.","DOI":"10.1038\/emi.2016.51"},{"issue":"48","key":"10.1016\/j.vaccine.2022.05.076_b0275","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.1016\/j.vaccine.2015.10.104","article-title":"A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice","volume":"33","author":"Jiang","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.076_b0280","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.imlet.2015.10.003","article-title":"Elicitation of HIV-1 neutralizing antibodies by presentation of 4E10 and 10E8 epitopes on Norovirus P particles","volume":"168","author":"Yu","year":"2015","journal-title":"Immunol Lett"},{"issue":"12","key":"10.1016\/j.vaccine.2022.05.076_b0285","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.2174\/0929866521666140616120955","article-title":"Development of a Norovirus P particle platform for eliciting neutralizing antibody responses to the membrane proximal external region of human immunodeficiency virus type 1 envelope","volume":"21","author":"Zang","year":"2014","journal-title":"Protein Pept Lett"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.076_b0290","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.imlet.2015.09.002","article-title":"Norovirus P particle: an excellent vaccine platform for antibody production against Alzheimer's disease","volume":"168","author":"Fu","year":"2015","journal-title":"Immunol Lett"},{"key":"10.1016\/j.vaccine.2022.05.076_b0295","doi-asserted-by":"crossref","first-page":"41041","DOI":"10.1038\/srep41041","article-title":"Norovirus P particle-based active Abeta immunotherapy elicits sufficient immunogenicity and improves cognitive capacity in a mouse model of Alzheimer's disease","volume":"7","author":"Fu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2022.05.076_b0300","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1475-2875-9-145","article-title":"Comparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacy","volume":"9","author":"Leitner","year":"2010","journal-title":"Malar J"},{"issue":"2","key":"10.1016\/j.vaccine.2022.05.076_b0305","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/vaccines9020103","article-title":"Orientation of antigen display on self-assembling protein nanoparticles influences immunogenicity","volume":"9","author":"Schneider","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2022.05.076_b0310","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/1475-2875-12-394","article-title":"Towards an optimized inhibition of liver stage development assay (ILSDA) for Plasmodium falciparum","volume":"12","author":"Zou","year":"2013","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2022.05.076_b0315","article-title":"Supramolecular self-assembled peptide-based vaccines: current state and future perspectives","volume":"8","author":"Abudula","year":"2020","journal-title":"Front Chem"},{"issue":"1","key":"10.1016\/j.vaccine.2022.05.076_b0320","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrd1284","article-title":"Therapeutic vaccination for chronic diseases: a new class of drugs in sight","volume":"3","author":"Bachmann","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2022.05.076_b0325","article-title":"Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: implications on HIV vaccine development","volume":"23\u201334","author":"Wagner","year":"1994","journal-title":"Behring Inst Mitt"},{"issue":"5","key":"10.1016\/j.vaccine.2022.05.076_b0330","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.4049\/jimmunol.1301692","article-title":"The carrier effect and T cell\/B cell cooperation in the antibody response","volume":"191","author":"Parker","year":"2013","journal-title":"J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22007010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22007010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:16:58Z","timestamp":1759403818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22007010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":66,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0264410X22007010"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.076","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Norovirus-VLPs expressing pre-erythrocytic malaria antigens induce functional immunity against sporozoite infection","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}